For those focused specifically on abdominal fat, the peptides for belly fat resource and the best peptide for visceral fat loss guide provide additional context on how GLP-1 and GIP agonists target different fat depots
Wegovy if prescribed for cardiovascular risk reduction in adults with obesity/overweight + established heart disease
Its January launch gave Novo a three-month head start on capturing customers before Lilly launched its competing Foundayo pill in April
What happens if it gets warm Brief exposure to room temperature, like during a dose draw, is fine
How should used patches be disposed of
Patients requiring multifactorial risk management : Individuals with multiple cardiovascular risk factors may benefit from the pleiotropic effects of GLP-1 therapy, including blood pressure reduction, weight loss, and lipid improvements